Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Frequently asked questions
What sector does Plus Therapeutics, Inc (PSTV) operate in?
Plus Therapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Plus Therapeutics, Inc (PSTV) current stock price?
As of the latest data, Plus Therapeutics, Inc stock price is $3.87, with a previous close of $3.87.
What is Plus Therapeutics, Inc (PSTV) current market capitalization?
Plus Therapeutics, Inc market cap is approximately 26.64 million.
What is Plus Therapeutics, Inc (PSTV) Earnings Per Share (EPS)?
The trailing EPS is $21.56, and the forward EPS is -$2.40.
What is Plus Therapeutics, Inc (PSTV) Price-to-Earnings (P/E) ratio?
Plus Therapeutics, Inc current P/E ratio is 0.18.
What is Plus Therapeutics, Inc (PSTV) EBITDA?
Plus Therapeutics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -9.06 million.
Does Plus Therapeutics, Inc (PSTV) pay dividends?
No. Plus Therapeutics, Inc does not pay a dividend.
What is Plus Therapeutics, Inc (PSTV) beta (volatility) score?
Plus Therapeutics, Inc has a beta of 1.419, suggesting it is more volatile than the market.
